Navigation Links
Global Ubiquitin Proteasome Research and Development Market to Surpass $5.5 Billion by 2018: BCC Research
Date:7/23/2013

Wellesley, MA (PRWEB) July 23, 2013

According to a new technical market research report, Ubiquitin Proteasome: Global Markets for Research Tools, Diagnostics and Drug Discovery (Report code: PHM066B) from BCC Research (http://www.bccresearch.com), the global ubiquitin proteasome research and development market was valued at nearly $2.9 billion in 2013. BCC Research expects the market to reach more than $5.5 billion by 2018, and register a five-year compound annual growth rate (CAGR) of 14.2% for the period 2013 to 2018.

Ubiquitin proteasome system (UPS) represents one of the most studied and challenging areas in basic and applicable science. The scientists who discovered this cellular phenomenon were awarded the Nobel Prize in Chemistry in 2004. Since then, ubiquitin ligases and proteasome function have become one of the major targets for pharmaceutical and drug development companies. However, despite the accumulation of basic knowledge about the ubiquitination process and proteasome function, progress in drug screening and therapeutic development has been delayed.

Until 2012, there was only one approved product on the market, Velcade (bortezomib), a proteasome inhibitor, and its success for Millennium Pharmaceuticals (a subsidiary of Takeda) as a major blockbuster pushed the industry towards more rigorous research and development. Velcade is a therapeutic treatment for patients with multiple myeloma, a type of bone marrow cancer that can damage one’s immune system.

According to BCC Research, the global market value of Velcade was more than $2 billion in 2012. The market is expected to reach $2.6 billion by 2013 and $4.5 billion by 2018, registering a CAGR of 11.4% for the period 2013 to 2018.

Today, there is new second-generation proteasome inhibitor on the market: Kyprolis, an immunomodulatory therapy marketed by Onyx Pharmaceuticals. The FDA approved Kyprolis in 2012 to treat patients who suffer from multiple myeloma and have received at least two prior therapies including treatment with Velcade. Many analysts predict that sales of this drug will increase dramatically in the next five years, depending on further applications and regulatory approvals. According to BCC Research, the global market value of Kyprolis was $62 million in 2012. This market is expected to reach $260 million by 2013 and further increase to $1 billion by 2018, to register a CAGR of 30.9% for the period 2013 to 2018.

Recent developments in the field of proteasome inhibitors bring new perspective and alternatives that may change the current market. This report details the current state of drug discovery in this field and new technologies in development and describes potential novel commercial venues in diagnostics and drug development. This study discusses the major players, current and future trends, influences, drivers and challenges for each segment, and includes forecasts for the next five years.

This report is intended for business development professionals, entrepreneurs and other investors who need to fully understand and properly evaluate each segment in the market for ubiquitin proteasome drug discovery, diagnostics, and research tools applications.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10941846.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Global Printed and Flexible Sensors 2013 Report: Forecasts, Players, Opportunities
2. Global Graphite Market 2012-2016
3. Global Activated Carbon Market 2012-2016: Latest Market Share, Growth, Analysis, Size, Trends & Forecast Research Report 2012-2016 Available at Marketresearchreports.biz
4. US Dermatophytic Onychomycosis Market Discussed by GlobalData in Topical Report Now Available at MarketPublishers.com
5. Global GIS Market in the Retail Industry to 2016: Industry Analysis, Growth, Strategy, Size, Shares, Trend and Forecast Research Report Available at MarketResearchReports
6. Growing Awareness & Increasing Number of Indications Drive the Global Intravenous Immunoglobulin Market, According to a New Report by Global Industry Analysts, Inc.
7. TriMix for Travel Now Available at KRS Global Biotechnology
8. Top Five Global Cardiovascular Drug Companies 2013 Report Features Players such as Pfizer and AstraZeneca
9. Stem Cells Market is Expected to Reach USD 119.51 Billion Globally in 2018: Transparency Market Research
10. Global Biometric Systems Market Forecast Report - Opportunities to 2018
11. NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), ... and plans to commercialize innovative therapeutics for patients ... stock were approved for trading on the OTCQX ... the OTCQX, effective today, under the ticker symbol ... market, companies must meet high financial standards, follow ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/8/2016)... 2016   Biocept, Inc . (NASDAQ: ... clinically actionable liquid biopsy tests to improve the ... featuring its Target Selector™ Circulating Tumor Cell platform ... detection of actionable biomarkers in patients with metastatic ... Sara Cannon Research Institute (SCRI), the research arm ...
(Date:12/7/2016)... McLean, VA (PRWEB) , ... December 07, 2016 ... ... peer-reviewed medical journal has concluded that “in the setting of previously treated, advanced ... Further refinement in defining the optimal patient population and timing of blood sampling ...
Breaking Biology Technology:
(Date:11/14/2016)... 14, 2016  xG Technology, Inc. ("xG" or the ... wireless communications for use in challenging operating environments, announced ... 2016. Management will hold a conference call to discuss ... Eastern Time (details below). Key Recent Accomplishments ... million binding agreement to acquire Vislink Communication Systems. The ...
(Date:6/22/2016)... 2016  The American College of Medical Genetics and Genomics ... as one of the fastest-growing trade shows during the ... Bellagio in Las Vegas . ... growth in each of the following categories: net square feet ... of attendees. The 2015 ACMG Annual Meeting was ranked 23 ...
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
Breaking Biology News(10 mins):